Skip to main content
VulnerabilityPublished Updated

CVE-2025-64298: Mirion Medical EC2 Software NMIS BioDose · Incorrect Permissions

Affects Mirion Medical EC2 Software NMIS BioDoseSource CVE Database V5

0

Not known to be exploited · CVSS 8.6 High.

Data as of 26 Oct 2026, 09:15 UTC

CVSS 4.0 base score
8.6High
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.2% chance of exploitation in 30 days – higher than 14% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

What to do

Affected software

ProductAffectedFixed in
Mirion Medical EC2 Software NMIS BioDoseAffected
  • =0
Fixed in–

AI-suggested

To mitigate CVE-2025-64298, organizations should immediately audit and restrict permissions on the Windows shares hosting the NMIS BioDose SQL Server database and configuration files. Access should be limited strictly to authorized service accounts and system administrators. Network segmentation should be enforced to isolate the affected systems from general user networks, reducing exposure to unauthorized clients. Implementing strict firewall rules and access control lists (ACLs) to limit SMB or file share access is critical. Regular monitoring and logging of access to these shares should be enabled to detect anomalous or unauthorized activity promptly. If possible, upgrade to a patched or newer version of the software once available from Mirion Medical. Until patches are released, consider deploying host-based intrusion detection systems (HIDS) and endpoint protection to detect suspicious behavior. Additionally, conduct user awareness training to highlight the risks of network share misconfigurations. Finally, ensure compliance with GDPR by documenting the vulnerability assessment and mitigation steps taken.

Description

NMIS/BioDose V22.02 and previous version installations where the embedded Microsoft SQLServer Express is used are exposed in the Windows share accessed by clients in networked installs. By default, this directory has insecure directory paths that allow access to the SQL Server database and configuration files, which can contain sensitive data.

References

Community reviews

Loading reviews…